A multi-centre phase two study of intravesical epirubicin in the treatment of superficial bladder tumour.

Abstract

Epirubicin (4'-epi-adriamycin) was used in the treatment of widespread superficial carcinoma of the bladder. Thirty-seven patients received 50 mg in 50 ml of saline retained for 60 min. There was an overall response rate of 59% but this was of short duration. Thirty percent of patients progressed despite therapy. Therapy was associated with an incidence of side effects which necessitated therapy withdrawal in 12 (32.4%) patients. It is concluded that epirubicin, in the dose used in this study, cannot be recommended for routine intravesical chemotherapy and that further studies, at a reduced dosage, are necessary to evaluate this agent.

Statistics

010002000'95'97'99'01'03'05'07'09'11'13'15'17
Citations per Year

245 Citations

Semantic Scholar estimates that this publication has 245 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Cumming1990AMP, title={A multi-centre phase two study of intravesical epirubicin in the treatment of superficial bladder tumour.}, author={J. A. Cumming and David L. Kirk and Donald W. W. Newling and Tim B. Hargreave and Peter J Whelan}, journal={European urology}, year={1990}, volume={17 1}, pages={20-2} }